Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

612
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
612
Cancer Vaccines01:30

Cancer Vaccines

469
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
469
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Towards a bioengineered airway: advances in tracheal tissue engineering and biofabrication.

Frontiers in cell and developmental biology·2026
Same author

Autophagy as an architect of embryogenesis: Understanding the new mechanisms, emerging paradigms, and future directions.

Life sciences·2026
Same author

Editorial: Synthetic biology and metabolomics: novel insight in oncology research.

Frontiers in bioengineering and biotechnology·2026
Same author

Microfluidics and 3D printed scaffolds for periodontal regeneration: A comprehensive review.

Dental materials : official publication of the Academy of Dental Materials·2025
Same author

Unveiling the Anti-cancer Potential of Oxadiazole Derivatives: A Comprehensive Exploration of Structure-Activity Relationships and Chemico-Biological Insights.

Medicinal chemistry (Shariqah (United Arab Emirates))·2025
Same author

Synthesis, crystal structure, and <i>in vitro</i> evaluation of newer 2,4-thiazolidinedione hybrids as α-glucosidase inhibitors.

Future medicinal chemistry·2025

Related Experiment Video

Updated: Aug 9, 2025

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

17.2K

Lung cancer immunotherapy: progress, pitfalls, and promises.

Aritraa Lahiri1, Avik Maji2, Pravin D Potdar3

  • 1Department of Biological Sciences, Indian Institute of Science Education and Research Kolkata, Mohanpur, Nadia, West Bengal, 741246, India.

Molecular Cancer
|February 22, 2023
PubMed
Summary

Lung cancer immunotherapy, including vaccines and checkpoint inhibitors, offers new hope. These treatments show promise for sustained responses in lung cancer patients, overcoming resistance and improving outcomes.

Keywords:
Adaptive cell therapyAntibodyCAR T therapyCancer VaccineImmunomodulatorsImmunotherapyLung CancerNSCLCNanomedicineSCLCTCR T therapyTIL therapy

More Related Videos

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.0K
Author Spotlight: Advancing Lung Transplant Immunology Through Intravital Imaging
04:16

Author Spotlight: Advancing Lung Transplant Immunology Through Intravital Imaging

Published on: April 19, 2024

1.1K

Related Experiment Videos

Last Updated: Aug 9, 2025

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

17.2K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.0K
Author Spotlight: Advancing Lung Transplant Immunology Through Intravital Imaging
04:16

Author Spotlight: Advancing Lung Transplant Immunology Through Intravital Imaging

Published on: April 19, 2024

1.1K

Area of Science:

  • Oncology
  • Immunology
  • Nanomedicine

Background:

  • Lung cancer remains a leading global cause of mortality, with conventional treatments often leading to resistance and relapse.
  • Immunotherapy is revolutionizing cancer care due to its safety, durable responses, and broad applicability.
  • Tumor-specific vaccination and adoptive cell therapies are emerging as key strategies in lung cancer treatment.

Purpose of the Study:

  • To provide a comprehensive overview of recent advancements in lung cancer immunotherapy.
  • To discuss adoptive cell therapies (CAR T, TCR, TIL) and their clinical applications in lung cancer.
  • To explore the role of nanomedicine and combination therapies in enhancing lung cancer immunotherapy.

Main Methods:

  • Review of recent clinical trials and scientific literature on lung cancer immunotherapy.
  • Analysis of programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) checkpoint blockade efficacy.
  • Examination of therapeutic cancer vaccines, adoptive cell therapies, and nanomedicine applications.

Main Results:

  • Significant and sustained responses observed in lung cancer patients treated with PD-1/PD-L1 checkpoint inhibitors, particularly those without targetable driver alterations.
  • Evidence suggests a link between the loss of anti-tumor immunity and lung tumor evolution.
  • Combination of therapeutic cancer vaccines with immune checkpoint inhibitors demonstrates enhanced therapeutic effects.

Conclusions:

  • Immunotherapy, including checkpoint inhibitors and vaccines, is a promising frontier for treating both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
  • Nanomedicine and combination strategies hold potential for improving immunotherapy efficacy.
  • Ongoing research and clinical trials are crucial for overcoming obstacles and advancing lung cancer immunotherapy.